Pediatric Rheumatology Collaborative Study Group – over four decades of pivotal clinical drug research in pediatric rheumatology

Table 2 Clinical trial outcome measures developed by the Pediatric Rheumatology Collaborative Study Group Leadership in collaboration with other pediatric rheumatology networks

PEDIATRIC RHEUMATIC DISEASE	Outcome measure	Reference
Juvenile Idiopathic Arthritis	Core set of Outcome Measures^a	[35]
	Preliminary Definition of Improvement^a	[36]
	Preliminary Flare Criteria^a	[37]
	Provisional criteria for inactive disease & clinical remission^a	[38]
	Macrophage Activation Syndrome^a	[39]
Systemic Lupus Erythematosus	Disease activity	[40]
	Disease damage	[41]
	Core Set of Outcome Measures^a	[42]
	Provisional Improvement Criteria^b	[43]
	Preliminary Flare Criteria^b	[44]
	Preliminary Inactive Disease Criteria^b	[45]
Juvenile Dermatomyositis	Childhood Myositis Activity Assessment Scale^c	[46]
	Core set measures of disease activity and damage^a	[42]
	Provisional Criteria for Response to Therapy^a	[47]

^aDeveloped in collaboration with Pediatric Rheumatology International Trials Organization (PRINTO)
^bDeveloped in collaboration with PRINTO and Childhood Arthritis and Rheumatology Research Alliance (CARRA)
^cDeveloped in collaboration with Juvenile Dermatomyositis Disease Activity Collaborative Study Group (predecessor to International Myositis Assessment and Clinical Studies Group)